IBEX (IBEX) Chief Legal Officer granted 19,557 shares, 2,176 withheld

Rhea-AI Filing Summary

IBEX Ltd’s Chief Legal Officer, Christina Alice Trofimuk-O'Connor, reported equity compensation activity. On February 6, 2026, she acquired 19,557 common shares at $0 as a restricted stock award tied to an April 20, 2022 performance share grant based on revenue and EBITDA targets.

On the same date, 2,176 common shares were disposed of at $34.98 to cover taxes due at vesting. After these transactions, she directly held 31,335 IBEX common shares. One-third of the award vested on February 6, 2026, with additional thirds scheduled to vest on February 6, 2027 and February 6, 2028, subject to her continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trofimuk-O'Connor Christina Alice

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/06/2026		A		19,557	A	$0(1)	33,511	D
Common Shares	02/06/2026		F		2,176(2)	D	$34.98	31,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person received this restricted stock award in connection with the vesting of an April 20, 2022 performance share award upon the attainment of certain Issuer Revenue and EBITDA targets for the trailing four (4) quarters. One-third of these shares vested on February 6, 2026. The remaining shares will vest one-third on February 6, 2027 and one-third on February 6, 2028. Vesting of performance share awards and shares issued in respect thereof is subject to the Reporting Person's continued service to the Company with Issuer through the applicable vesting date.

2. Represents shares withheld for tax purposes upon vesting of restricted stock grant.

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IBEX (IBEX) report for its Chief Legal Officer?

IBEX reported that Chief Legal Officer Christina Alice Trofimuk-O'Connor acquired 19,557 common shares as a restricted stock award. The award stems from a 2022 performance share grant tied to revenue and EBITDA targets, with vesting over three annual installments.

How many IBEX (IBEX) shares were withheld for taxes in this Form 4?

The filing shows 2,176 IBEX common shares were disposed of at $34.98 per share to satisfy tax obligations. These shares were withheld upon vesting of the restricted stock grant rather than sold as an open-market transaction.

What is the new IBEX (IBEX) shareholding of the Chief Legal Officer after the transactions?

Following the reported transactions, the Chief Legal Officer directly owns 31,335 IBEX common shares. This figure reflects the 19,557-share restricted stock acquisition and the 2,176 shares withheld to cover tax liabilities related to the vesting event.

What performance conditions are tied to the IBEX (IBEX) restricted stock award?

The restricted stock award was earned upon meeting revenue and EBITDA targets measured over four trailing quarters. It relates to an April 20, 2022 performance share award that converted into shares once those specified financial performance thresholds were achieved.

What is the vesting schedule for the IBEX (IBEX) restricted stock reported in this Form 4?

One-third of the restricted shares vested on February 6, 2026. The remaining two-thirds are scheduled to vest in equal installments on February 6, 2027 and February 6, 2028, contingent on the executive’s continued service with IBEX.

Is the IBEX (IBEX) Chief Legal Officer’s equity award subject to continued employment conditions?

Yes. The filing states that vesting of the performance share awards, and the shares issued from them, depends on the reporting person’s continued service with the company through each applicable vesting date, adding a retention component to the compensation.